- Innovent Biologics partnered with Spero Therapeutics Inc. to advance the development of IBI355.
- HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.
GSK Out-Licenses Commercial Rights for Spero Therapeutics Drug
What happened
GSK granted out-licensing rights for Spero Therapeutics' first drug. Spero Therapeutics recently completed a $105 million financing transaction through the partial monetization of commercial milestones tied to that product. The company plans to initiate a Phase II trial of its lead candidate, SP001, in IgG4-RD in the second quarter of 2027.
From tickerreport.com
Why it matters
The out-licensing of the drug increases GSK's pipeline and potential revenue. Spero Therapeutics used the monetization of commercial milestones to secure $105 million in financing, which is expected to extend its cash runway into the second half of 2029.
HCRx bought into Utebzi milestones and royalties, and GSK granted an exclusive license for Utebzi. Innovent Biologics partnered with Spero Therapeutics to advance the development of IBI355.
From tickerreport.com
Who's involved
- GSKBritish multinational pharmaceutical and biotechnology company that granted the out-licensing rights.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- GSKSpeculative
GSK might see increased revenue potential and a larger pipeline due to gaining commercial rights to Spero's drug.
Keep exploring
The entities involved
-
GSK
British multinational pharmaceutical and biotechnology company